Lilly reports adults with type 2 diabetes lost 19.5% to 20.9% of body weight on retatrutide versus 9.4% on Ozempic 2 mg at 80 weeks, with a 2.2% A1C drop.
Recap by typeshit. Full story at Yahoo Finance.
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
The Scientist weighs whether GLP-1 drugs could lengthen life and finds the answer still unsettled. Tap through for where the research stands.
The Times looks at current options for the facial volume loss that can come with rapid GLP-1 weight loss. Full details are on the site.
Loading…